Status:
RECRUITING
Clinical Translation of a Novel Brain PET Insert for Simultaneous PET/MR
Lead Sponsor:
Stanford University
Conditions:
Brain Disease
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
The primary goal of this project is to study the feasibility of a brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of human brains. The study will also allow ...
Detailed Description
This study will enroll up to 40 participants. 1. 20 participants at Stanford injected with an FDA-approved PET tracer (e.g. amyloid, FDG, etc.), and 2. 20 participants from Stanford who have been pre...
Eligibility Criteria
Inclusion
- Whole body radiation dose within the last year of less than 5000 mrem
- Subjects intended for injected tracer studies (not associated with another study) must be willing/able to undergo injection of 6-12 mCi of either FDG or Neuraceq radiotracer. Both tracers are FDA approved
- Subjects will be at least 21 years of age
- Subject provides written informed consent
- Subject is deemed healthy by the PI by via self-reported questionnaire
Exclusion
- For patients who will be receiving a tracer injection, no known allergy to the imaging agents
- Participant has a history of or current diagnosis of cancer
- Participant is pregnant or nursing
- Metallic implants (contraindicated for MRI)
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2028
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04383808
Start Date
April 1 2025
End Date
March 31 2028
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Palo Alto, California, United States, 94305